2024
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, Krug R, Cowling B, Meyers L. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. ELife 2024, 13: e89801. PMID: 38622989, PMCID: PMC11078542, DOI: 10.7554/elife.89801.Peer-Reviewed Original ResearchConceptsViral sheddingHospitalized COVID-19 patientsSARS-CoV-2Retrospective cohort studyRisk of reboundCOVID-19 patientsViral reboundTime of treatmentTreated patientsPreventing severe illnessEarly treatmentCohort studyHospitalized patientsPatientsViral replicationReducing infectiousnessSevere illnessTimely treatmentViral dynamicsHealth record dataTreatmentTransmission riskTransmission of SARS-CoV-2EfficacySymptoms
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply